ICAD: AI 评分 54/100 — AI 分析 (4月 2026)

iCAD, Inc. specializes in cancer detection and therapy solutions, leveraging image analysis and AI. The company operates through two segments, offering products like ProFound AI and Xoft Axxent to improve cancer care.

Key Facts: Price: $3.87 AI Score: 54/100 Sector: Healthcare

公司概况

概要：

iCAD, Inc. pioneers AI-powered cancer detection and therapy solutions, offering innovative platforms like ProFound AI and Xoft Axxent. With a focus on early detection and targeted treatment, iCAD aims to improve patient outcomes and drive growth in the medical device market, despite current profitability challenges.

ICAD是做什么的？

iCAD, Inc., founded in 1984 as Howtek, Inc. and rebranded in 2002, is a medical technology company focused on providing advanced image analysis, workflow solutions, and radiation therapy technologies for cancer treatment. Headquartered in Nashua, New Hampshire, iCAD operates through two primary segments: Cancer Detection and Cancer Therapy. The Cancer Detection segment features the PowerLook platform, which hosts AI algorithms and manages communication between imaging systems. Key products include SecondLook, an AI-driven tool for 2D mammography analysis, and ProFound AI, a deep-learning algorithm for digital breast tomosynthesis, designed to detect malignant tissues. The company also offers ProFound AI Risk, a tool for breast cancer risk estimation, and MRI applications for breast and prostate cancer detection. The Cancer Therapy segment offers the Xoft Axxent electronic brachytherapy system, used for treating early-stage breast, skin, and gynecological cancers. iCAD sells its products through direct sales, OEM partners, distributors, and resellers, with a global presence including Europe, Taiwan, Canada, and China. Despite a negative profit margin of -24.1%, iCAD maintains a high gross margin of 86.2%, reflecting the value of its technology.

ICAD的投资论点是什么？

Investing in iCAD presents a compelling opportunity due to its innovative AI-driven cancer detection technologies, particularly ProFound AI, which enhances the accuracy and efficiency of breast cancer screening. The increasing adoption of digital breast tomosynthesis and the growing demand for AI-powered diagnostic tools are key growth catalysts. iCAD's expansion into new markets and applications, such as prostate cancer detection and risk assessment, further strengthens its growth potential. While the company currently operates at a loss (P/E of -29.64), strategic partnerships and increasing sales of its high-margin products are expected to drive profitability. The company's high beta of 1.40 indicates higher volatility than the market, which could provide opportunities for aggressive investors. The company's market cap is $0.11B as of 2026-02-09.

ICAD在哪个行业运营？

iCAD operates in the medical device industry, specifically focusing on cancer detection and therapy. The industry is experiencing growth driven by technological advancements in AI and medical imaging. The increasing prevalence of cancer and the growing demand for early and accurate detection methods are fueling market expansion. iCAD competes with companies like ASXC (Ascent Solar Technologies), AUGX (Augmedix), CYT (Cytek Biosciences), FVE (Five Nines, Inc.), and GENE (Genetic Technologies Ltd), which offer various diagnostic and therapeutic solutions. iCAD's focus on AI-powered image analysis and targeted radiation therapy positions it to capitalize on these trends, offering innovative solutions that improve patient outcomes and reduce healthcare costs.

Medical - Devices

Healthcare

ICAD有哪些增长机遇？

Expansion of ProFound AI into New Markets: ProFound AI has the potential to expand beyond breast cancer detection into other imaging modalities and cancer types, such as lung and prostate cancer. The market for AI in medical imaging is projected to reach $2 billion by 2028, offering a significant growth opportunity for iCAD. Timeline: Ongoing.
Strategic Partnerships with Imaging Equipment Manufacturers: Collaborating with leading imaging equipment manufacturers to integrate iCAD's AI algorithms into their systems can drive adoption and increase market penetration. These partnerships can provide access to a broader customer base and accelerate revenue growth. Timeline: Ongoing.
Increased Adoption of Xoft Axxent System: The Xoft Axxent system offers a less invasive and more targeted approach to radiation therapy, which can lead to increased adoption among hospitals and cancer centers. The market for brachytherapy systems is expected to grow at a CAGR of 5% over the next five years. Timeline: Ongoing.
Development of New AI-Powered Diagnostic Tools: Investing in research and development to create new AI-powered diagnostic tools for various cancers can expand iCAD's product portfolio and address unmet clinical needs. This includes developing solutions for early detection, risk assessment, and personalized treatment planning. Timeline: Ongoing.
Geographic Expansion into Emerging Markets: Expanding into emerging markets, such as Asia and Latin America, can provide access to new customer segments and drive revenue growth. These markets are experiencing increasing healthcare spending and a growing demand for advanced medical technologies. Timeline: Ongoing.

High Gross Margin of 86.2% demonstrates the pricing power and value of iCAD's technology.
ProFound AI offers a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis.
Xoft Axxent electronic brachytherapy system provides targeted treatment for early-stage cancers, reducing side effects compared to traditional radiation therapy.
iCAD operates in two segments: Cancer Detection and Cancer Therapy, diversifying its revenue streams.
Beta of 1.40 indicates higher volatility than the market, which could provide opportunities for aggressive investors.

ICAD提供哪些产品和服务？

Develops and markets image analysis software for cancer detection.
Offers AI-powered solutions for mammography and tomosynthesis.
Provides radiation therapy systems for targeted cancer treatment.
Creates tools for breast cancer risk assessment.
Offers solutions for colon polyp detection.
Exports products to Europe, Taiwan, Canada, and China.

ICAD如何赚钱？

Sells software and hardware solutions for cancer detection and therapy.
Generates revenue through direct sales and partnerships with OEMs.
Offers service and maintenance contracts for its systems.
Provides training and support to healthcare professionals.

Hospitals and cancer centers.
University research facilities.
Cancer care clinics.
Veterinary facilities and dermatology offices.

Proprietary AI algorithms for cancer detection.
Strong relationships with imaging equipment manufacturers.
Established market presence in the cancer detection and therapy space.
Xoft Axxent system offers a unique approach to radiation therapy.

什么因素可能推动ICAD股价上涨？

Upcoming: FDA approvals for new AI-powered diagnostic tools.
Ongoing: Increasing adoption of ProFound AI in breast cancer screening.
Ongoing: Expansion of Xoft Axxent system into new hospitals and cancer centers.
Ongoing: Strategic partnerships with imaging equipment manufacturers to integrate iCAD's AI algorithms.
Ongoing: Geographic expansion into emerging markets.

ICAD的主要风险是什么？

Potential: Failure to achieve profitability due to high operating expenses.
Potential: Competition from larger medical device companies with greater resources.
Potential: Regulatory changes and reimbursement policies affecting the adoption of iCAD's products.
Ongoing: Technological obsolescence and the need to continuously innovate.
Ongoing: Economic downturns affecting healthcare spending and demand for iCAD's solutions.

ICAD的核心优势是什么？

Innovative AI-powered cancer detection technologies.
High gross margin (86.2%).
Proprietary Xoft Axxent system for targeted radiation therapy.
Established partnerships with OEMs and distributors.

ICAD的劣势是什么？

Negative profit margin (-24.1%).
High beta (1.40) indicates higher volatility.
Reliance on a limited number of products and services.
Relatively small market capitalization ($0.11B).

ICAD有哪些机遇？

Expansion into new markets and applications (e.g., prostate cancer).
Increased adoption of digital breast tomosynthesis.
Growing demand for AI-powered diagnostic tools.
Strategic partnerships with imaging equipment manufacturers.

ICAD面临哪些威胁？

Competition from larger medical device companies.
Regulatory changes and reimbursement policies.
Technological obsolescence.
Economic downturns affecting healthcare spending.

ICAD的竞争对手是谁？

Ascent Solar Technologies — Focuses on solar power solutions. — (ASXC)
Augmedix — Provides AI-powered medical documentation services. — (AUGX)
Cytek Biosciences — Offers cell analysis tools and solutions. — (CYT)
Five Nines, Inc. — Provides managed IT services. — (FVE)
Genetic Technologies Ltd — Focuses on genetic testing for disease risk assessment. — (GENE)

Key Metrics

Price: $3.87 (+3.75%)
Market Cap: $106.3M
Volume: 190,127
MoonshotScore: 54/100

Company Profile

CEO: Dana R. Brown
Headquarters: Nashua, NH, US
Employees: 66
Founded: 1984

AI Insight

常见问题

What does iCAD, Inc. do?

iCAD, Inc. is a medical technology company that develops and markets advanced image analysis, workflow solutions, and radiation therapy technologies for cancer treatment. The company operates through two segments: Cancer Detection and Cancer Therapy. Its Cancer Detection segment offers AI-powered solutions for mammography and tomosynthesis, including ProFound AI, which enhances the accuracy and efficiency of breast cancer screening. The Cancer Therapy segment provides the Xoft Axxent electronic brachytherapy system for targeted treatment of early-stage cancers. iCAD's products are sold through direct sales, OEM partners, and distributors to hospitals, cancer centers, and research facilities worldwide.

Is ICAD stock a good buy?

ICAD stock presents a speculative investment opportunity. While the company boasts innovative AI-driven cancer detection technologies and a high gross margin of 86.2%, it currently operates at a loss with a P/E of -29.64. Key growth catalysts include increasing adoption of ProFound AI and expansion into new markets. However, potential risks include competition, regulatory changes, and the need to achieve profitability. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in ICAD.

What are the main risks for ICAD?

The main risks for iCAD include its current lack of profitability, intense competition from larger medical device companies, and potential regulatory changes affecting the adoption of its products. The company's high beta of 1.40 indicates higher volatility than the market, which could lead to significant price fluctuations. Additionally, technological obsolescence and economic downturns affecting healthcare spending could negatively impact iCAD's growth prospects. Successfully navigating these risks is crucial for iCAD to achieve its long-term goals.